Ceftazidime in Gram-Negative Resistance Research

Ceftazidime is a third-generation cephalosporin used in laboratory studies of bacterial susceptibility, cell-wall-active antibiotics, and resistance phenotypes. Its notable in vitro activity against Pseudomonas aeruginosa makes it a useful comparator in Gram-negative bacterial infection research. It can also help researchers ask a more specific question: does a resistance determinant or mobile genetic element coincide with a change in the measured response to this cephalosporin?

The distinction between a useful test compound and a treatment recommendation matters. An in vitro result describes an organism under defined assay conditions; it does not by itself predict clinical outcomes. The product’s reported properties, including its DMSO solubility and storage guidance, are summarized on the Ceftazidime product page. APExBIO supplies the research reagent. The workflow below is intended for controlled laboratory investigation, not patient care.

Setup and principle: what Ceftazidime can reveal

Ceftazidime inhibits bacterial cell-wall synthesis and can produce bactericidal effects in susceptible bacteria. As a broad-spectrum antibiotic with particular relevance to aerobic Gram-negative organisms, it is frequently considered in studies involving P. aeruginosa and other susceptible Gram-negative species. Activity is not uniform across all bacteria: its activity against Staphylococcus aureus, for example, is lower than that of first- and second-generation cephalosporins.

In a susceptibility experiment, the practical readout is commonly growth across a concentration series, with a minimum inhibitory concentration (MIC) determined according to the chosen method and interpretive standard. For resistance research, that readout becomes more informative when paired with isolate identity, genotype, and appropriate controls. Ceftazidime is described as relatively resistant to hydrolysis by some β-lactamases, but this general property does not mean every β-lactamase producer will be susceptible. Enzyme class, expression, permeability, strain background, and other resistance features can all affect the observed phenotype.

That context is especially important for carbapenem-resistant Enterobacter cloacae (CREC). Carbapenemase-encoding genes signal a resistance problem, but their presence alone should not be treated as a ceftazidime susceptibility result. Test the compound directly, report the method and conditions, and interpret MIC values using current, applicable standards rather than extrapolating from gene detection alone.

Key Innovation from the Reference Study

The 2025 study of carbapenemase-encoding genes in CREC from eight teaching hospitals in Guangdong examined 54 isolates collected between December 2022 and June 2024. Carbapenemase-encoding genes were detected in 46 of 54 isolates (85.19%). The investigators combined broth microdilution with a variable-temperature SDS plasmid-elimination method, PCR, plasmid conjugation, and ERIC-PCR typing. This linked antimicrobial phenotypes to gene location, transfer potential, and strain relatedness rather than treating resistance as a single endpoint.

Among the 54 isolates, 18 (33.33%) carried bla_NDM-1 on both chromosomes and plasmids, while 25 (46.30%) carried it exclusively on plasmids. Conjugation transferred carbapenemase-encoding genes in 44 of 46 relevant isolates (95.65%). ISEcp1 was the most frequently identified mobile genetic element, present in 47 of 54 isolates (87.04%). These findings make a practical case for asking both where a resistance gene is located and whether it can move between bacteria.

The study also reported higher resistance in the gene-positive group to imipenem, cefepime, gentamicin, ceftazidime/avibactam, ciprofloxacin, and levofloxacin. That finding concerns the tested ceftazidime/avibactam combination; it must not be presented as a direct result for ceftazidime alone. For a Ceftazidime experiment, measure Ceftazidime as its own condition, and treat any inhibitor combination as a separate assay arm with its own controls and validated procedure.

For experimental planning, the study’s key methodological lesson is to pair a standardized susceptibility assay with molecular characterization. If the question concerns gene mobility, add a transfer experiment and confirm recipients molecularly. If the question concerns clonal spread, include a strain-typing method. These additions help distinguish a resistant phenotype associated with a transferable plasmid from one found in related isolates, although no single assay establishes every mechanism.

Step-by-step workflow and protocol enhancements

1. Define the comparison before preparing the assay

Specify whether the study tests baseline susceptibility, a gene-positive versus gene-negative comparison, or the effect of a defined genetic or environmental change. Select isolates with documented identity and maintain a record linking each culture to its genotype and passage history. Include a susceptible comparator and a suitable quality-control organism selected according to the current standard used by your laboratory. When studying CREC, avoid selecting only highly resistant isolates: a balanced panel can reveal whether a phenotype tracks with a gene, a plasmid, or a broader strain background.

2. Prepare and verify the compound

The product is supplied as a solid and is reported soluble in DMSO at concentrations of at least 21.25 mg/mL, but insoluble in water and ethanol. Prepare a small DMSO stock using aseptic handling, inspect it for visible particulates, and label concentration, solvent, preparation date, and storage conditions. Follow the product guidance to store the compound at −20°C and stock solutions below −20°C; use prepared solutions promptly and minimize repeated freeze–thaw cycles. Include a vehicle-only control, because DMSO itself can influence bacterial growth at sufficient concentrations.

3. Run a concentration-response assay

Use a broth microdilution workflow appropriate to the organism and the current laboratory standard. Prepare a dilution series that brackets the expected response rather than assuming a universal range. Standardize the inoculum, use consistent well volumes, and include growth, sterility, and vehicle controls on each plate. Confirm inoculum density by viable-count plating when the study requires a particularly rigorous MIC comparison. Record the medium, inoculum, incubation conditions, plate format, and endpoint rule so results can be reproduced.

4. Connect phenotype to molecular evidence

For isolates with differing MICs, test the relevant resistance genes and, where appropriate, examine plasmid association or transfer. The Guangdong study used PCR after plasmid elimination to help distinguish chromosomal from plasmid-associated gene carriage, then used conjugation and PCR to assess transfer. A laboratory adapting these approaches should validate its own controls and confirm that the plasmid-elimination procedure does not simply remove or select for the organisms of interest. Keep susceptibility, gene detection, gene location, and transfer as separate measurements in the analysis.

Protocol Parameters

The values below are practical starting conditions for an exploratory assay, not values reported as the study’s complete protocol or a substitute for current CLSI/EUCAST guidance. Validate the conditions for the organism, medium, and intended interpretation.

• Stock preparation: Prepare a 10 mg/mL Ceftazidime stock in DMSO; mix until visually clear, aliquot, and store below −20°C. Use promptly after thawing and record each freeze–thaw event.
• Concentration series: For an initial pilot, prepare two-fold final concentrations from 0.25 to 256 µg/mL in broth. Adjust the range after a pilot so that the measured endpoint is bracketed rather than falling outside the tested concentrations.
• Inoculum and well volume: Prepare a bacterial suspension at 1 × 10⁶ CFU/mL, then combine 100 µL of that suspension with 100 µL of 2× drug solution per well to give a nominal final inoculum of 5 × 10⁵ CFU/mL in 200 µL.
• Incubation: As an exploratory starting point, incubate the inoculated plate at 35 ± 2°C for 16–20 hours. Apply the endpoint and any organism-specific deviations required by the current method your laboratory follows.
• Vehicle control: Match the final DMSO fraction in the drug wells with vehicle-only wells; include a growth control without Ceftazidime and a sterility control without bacteria. Confirm in a pilot that the selected DMSO fraction does not measurably suppress growth.

Advanced applications and comparative advantages

One useful application is comparative Gram-negative bacterial infection research: measure Ceftazidime response alongside organism identity and resistance markers to determine whether changes in the phenotype accompany a defined experimental condition. In P. aeruginosa work, the compound can serve as a relevant cephalosporin comparator, while a panel of other antibiotics can help show whether the observed shift is compound-specific or part of a broader resistance pattern. Do not describe the drug as universally effective against Pseudomonas; the product information notes that resistance can occur in some strains.

A second application is studying respiratory isolates in vitro. The Guangdong report found the highest isolate counts in respiratory medicine and sputum samples among its reported clinical categories: 11 of 54 isolates (20.37%) and 18 of 54 (33.33%), respectively. Those descriptive findings can inform sampling priorities for surveillance research, but they do not establish that Ceftazidime treats an individual infection or that the study tested a Ceftazidime-alone treatment outcome. For the same reason, laboratory work related to the treatment of bacterial pneumonia or treatment of bacterial bronchitis should be framed as pathogen or susceptibility research, not clinical dosing advice.

For broader resistance context, the related article Transmission of Carbapenemase Genes in CREC: Guangdong Study Insights complements this workflow by emphasizing plasmid carriage and transfer. The article Ceftazidime: Resistance Mechanisms and Research-Grade Protocols extends the discussion toward assay planning and resistance interpretation. Use these as related reading, not as a replacement for validated methods or primary data.

Troubleshooting and optimization tips

• Unexpected precipitation: Ceftazidime is not soluble in water or ethanol according to the product information. Prepare the stock in DMSO, inspect it before use, and avoid transferring visible particles into assay wells. If a working dilution becomes cloudy, do not assume the nominal concentration is bioavailable; remake the dilution and reassess the preparation sequence.
• Growth inhibition in vehicle controls: DMSO can confound an apparent antibiotic effect. Match the solvent concentration across comparison wells, test the vehicle alone, and reduce solvent carryover where feasible without compromising compound solubility. If the required range cannot be tested without a solvent effect, redesign the concentration range or consult the validated method for an appropriate formulation.
• MIC values vary between runs: Check inoculum density, culture age, medium, dilution accuracy, incubation conditions, and plate reading criteria. Use the same method across study groups and include a reference control in every run. Do not pool results from different methods without a prespecified harmonization plan.
• All wells grow or none grow: If all wells grow, extend or shift the concentration range only after checking stock concentration, dilution calculations, and compound handling. If all wells show inhibition, verify the inoculum and vehicle controls, then test a lower range. An endpoint outside the tested range is not a precise MIC.
• Genotype and phenotype appear inconsistent: A detected carbapenemase gene does not prove a specific Ceftazidime phenotype. Confirm isolate identity and assay quality, consider additional resistance mechanisms, and report gene detection separately from susceptibility. In particular, do not use the study’s ceftazidime/avibactam result as a surrogate for Ceftazidime alone.

Future outlook

The Guangdong findings highlight the value of combining susceptibility measurements with gene-location, transfer, and strain-relatedness data. For Ceftazidime research, that means making the antibiotic concentration-response experiment one part of a transparent evidence chain rather than a standalone claim about resistance. Larger isolate panels, careful controls, and reproducible molecular confirmation can help researchers distinguish local strain relationships from the wider dissemination of mobile resistance determinants. The most useful next step is not to infer more than the data show, but to design experiments that connect a measured phenotype to a clearly tested biological question.